

April 13, 2026

To
The Manager,
Department of Corporate Services
BSE Limited,
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

Scrip Symbol: 543064

Dear Sir/Madam,

Sub: Clarification on Increase in volume.

This is in reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and with respect to BSE Email ref no. L/SURV/ONL/PV/SG/2026-2027/36 dated April 13, 2026, seeking clarification on the increase in volume of the shares of the Company traded across the Exchanges in the recent past.

The Company confirms that there is no pending information and/or announcement which, in terms of Regulation 30 of the SEBI Listing Regulations is required to be disclosed to the Stock Exchanges and which, in our opinion, may have a bearing on the price/volume behaviour of the Company's scrip.

Further, we would like to state that the movement in the volume of equity shares of the Company is purely market-driven and attributable to prevailing market conditions.

The Company has been regularly notifying all Unpublished Price Sensitive Information ("UPSI"), as and when required, in compliance with Regulation 30 and other applicable provisions of the SEBI Listing Regulations.

This above clarification may please be taken on record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Sisir K. Mishra
Company Secretary & Compliance Officer

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

